Hdac Inhibitor Cxd101
Hdac Inhibitor Cxd101 Uses, Dosage, Side Effects, Food Interaction and all others data.
Hdac Inhibitor Cxd101 is under investigation in clinical trial NCT03873025 (A Study of Hdac Inhibitor Cxd101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
| Trade Name | Hdac Inhibitor Cxd101 |
| Generic | CXD101 |
| CXD101 Other Names | Hdac inhibitor cxd101, Hdac-in-4 |
| Type | |
| Formula | C24H29N5O |
| Weight | Average: 403.53 Monoisotopic: 403.237210574 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Hdac Inhibitor Cxd101
